Mixed mold infection with Aspergillus fumigatus and Rhizopus microsporus in a severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2) patient

Bellanger, Anne‐Pauline; Navellou, Jean-Christophe; Lepiller, Quentin; Brion, Annie; Brunel, Anne-Sophie; Millon, Laurence; Berceanu, Ana

doi:10.1016/j.idnow.2021.01.010

Cited by 63 publications

(65 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The papers (case reports and case series) reported 100 patients including present case report ( Table 1 ) [ [10] , [11] , [12] , [13] , [14] , [15] , [16] , [17] , [18] , [19] , [20] , [21] , [22] , [23] , [24] , [25] , [26] , [27] , [28] , [29] , [30] , [31] , [32] , [33] , [34] , [35] , [36] , [37] , [38] , [39] ]. The majority of the patients were presented from India (7 case reports and 5 case series, a total of 68, 68%), followed by Turkey (12), USA (9), Iran (3), Spain (2), United Kingdom (1), Brasil (1), Italy (1), France (1), Mexico (1), and Austria (1).…”

Section: Resultsmentioning

confidence: 99%

COVID-19-associated mucormycosis: Case report and systematic review

Dilek

Özaras²,

Özkaya

et al. 2021

Travel Medicine and Infectious Disease

View full text Add to dashboard Cite

Section: Resultsmentioning

confidence: 99%

COVID-19-associated mucormycosis: Case report and systematic review

Dilek

Özaras²,

Özkaya

et al. 2021

Travel Medicine and Infectious Disease

View full text Add to dashboard Cite

“…The most commonly reported infection sites were rhino-orbital/rhino-cerebral mucormycosis[ 24 – 26 , 30 , 32 – 37 , 40 , 42 , 45 , 47 , 52 – 54 ]. Other presentations included pulmonary [ 31 , 41 , 43 , 44 , 49 , 51 , 55 ], cutaneous [ 46 ], disseminated [ 56 ] and gastrointestinal [ 48 ] diseases. The reported organisms were Rhizopus spp.…”

Section: Clinical Features and Managementmentioning

confidence: 99%

“…The reported organisms were Rhizopus spp. [ 24 , 31 , 36 , 41 – 44 , 47 , 49 , 51 , 55 ] and the others were reported as unspecified Mucorale [ 25 , 26 , 30 , 33 – 35 , 37 , 40 , 45 , 48 , 50 , 52 , 54 ]. The management of mucormycosis is usually difficult and requires urgent medical and surgical debridement while the choice of drug to treat mucormycosis is Amphotericin B [ 23 , 57 ] and Amphotericin was used in 23 of the included studies [ 24 – 26 , 30 – 37 , 40 – 44 , 46 , 47 , 49 – 54 ] and surgical debridement was reported in 20 of the included studies [ 24 – 26 , 30 , 32 – 37 , 40 , 44 – 47 , 50 – 54 ].…”

Section: Clinical Features and Managementmentioning

confidence: 99%

COVID-19 and mucormycosis superinfection: the perfect storm

et al. 2021

View full text Add to dashboard Cite

Background The recent emergence of the Coronavirus Disease (COVID-19) disease had been associated with reports of fungal infections such as aspergillosis and mucormycosis especially among critically ill patients treated with steroids. The recent surge in cases of COVID-19 in India during the second wave of the pandemic had been associated with increased reporting of invasive mucormycosis post COVID-19. There are multiple case reports and case series describing mucormycosis in COVID-19. Purpose In this review, we included most recent reported case reports and case-series of mucormycosis among patients with COVID-19 and describe the clinical features and outcome. Results Many of the mucormycosis reports were eported from India, especially in COVID-19 patients who were treated and recovered patients. The most commonly reported infection sites were rhino-orbital/rhino-cerebral mucormycosis. Those patients were diabetic and had corticosteroids therapy for controlling the severity of COVID-19, leading to a higher fatality in such cases and complicating the pandemic scenario. The triad of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), corticosteroid use and uncontrolled diabetes mellitus have been evident for significant increase in the incidence of angioinvasive maxillofacial mucormycosis. In addition, the presence of spores and other factors might play a role as well. Conclusion With the ongoing COVID-19 pandemic and increasing number of critically ill patients infected with SARS-CoV-2, it is important to develop a risk-based approach for patients at risk of mucormycosis based on the epidemiological burden of mucormycosis, prevalence of diabetes mellitus, COVID-19 disease severity and use of immune modulating agents including the combined use of corticosteroids and immunosuppressive agents in patients with cancer and transplants.

show abstract

“…The increasing number of recent case series of mucormycosis complicating COVID-19 patients in the United States, 10 – 16 Austria, 17 Brazil, 18 Mexico, 19 Italy, 20 France, 21 Iran, 22 – 24 and India, 25 – 34 raises concerns regarding the misuse of immunosuppressive drugs in patients with COVID-19. Mucormycosis is a neglected mycosis that should be considered in the context of patients with COVID-19, in the same way as COVID-19 associated pulmonary aspergillosis, and it is possibly underreported.…”

mentioning

confidence: 99%